This article summarizes studies designed to evaluate the role of Helicobacter pylori infection in Chile, described in 21 reports from nine centers in various Chilean regions published between 1985 and 1995. According to their data, H. pylori infection is quite frequent among patients with a variety of gastric conditions, including adults (43% -92%) and children (6% -100%). Levels of specific IgG antibodies to H. pylori are also elevated among patients with duodenal ulcers (100%) and gastritis (86%) as well as asymptomatic adults (75%). Combination therapy with three (but not two) drugs has been proved effective, with clinical improvement, ulcer cure, and H. pylori eradication occurring in well-controlled studies. Available evidence suggests that antibiotic resistance is not a major problem in treatment. The H. pylori reinfection rate is low (4.2% per year), suggesting that combination therapy with three drugs constitutes a cost-effective alternative for treating colonized symptomatic patients. Concurrent preliminary studies revealed that antibodies to VacA but not CagA proteins correlate with disease severity in Chilean patients. It can be concluded that local research assists local administrators of health resources to implement adequate policies to prevent, control, and treat H. pylori -related pathologies.
There is overwhelming evidence to support the pathogenic tional journals. Almost all the available information on H. pylori is from university research centers, including a total role of Helicobacter pylori in type B gastritis, gastroduodenal ulcers, and possibly some types of gastric cancer. This concept of 8 teams (covering 6 different regions; figure 1 ), at the University of Chile (4), Catholic University of Chile in Santiago has produced profound changes in the diagnosis, treatment, and prognosis of gastrointestinal (GI) pathologies. Every effort (1) , University of Antofagasta (1), University of Concepcion (1) , and University Austral in Valdivia (1) . In addition, two should be made to optimize diagnosis, treatment, control, and eventual prevention of H. pylori -associated GI diseases all groups from the University of Maryland (College Park, MD) conducted collaborative research, one with the Catholic Uniover the world, particularly in developing countries, where the infection rates are higher.
versity and the other with investigators at the Public Health Institute, both in Santiago. Most of these studies had financial Chile is a developing country with a population of Ç15 million, a sustained growing economy, and drastic epidemiosupport from FONDECYT, a governmental granting agency for scientific research. The following pages summarize most logical changes in public health. Important improvements in health indicators have occurred in the past 40 years: infant relevant results, arbitrarily divided as basic or epidemiological information. mortality, malnutrition, and infectious diarrhea, once prevalent, are now less important, while obesity, coronary diseases, and diabetes have become more common conditions. In this sceBasic Studies on H. pylori nario some chronic GI diseases, in particular duodenal ulcers (DUs) and gastric cancer, have become major causes of consulSeveral basic protocols have been used to study virulence tation [1] . The purpose of this report is to summarize studies determinants of H. pylori strains as well as their impact on the performed in Chile relating to H. pylori and gastroduodenal immune system of symptomatic and asymptomatic Chilean conditions. individuals. After an exhaustive review we found that in the 10 years following December 1985 a total of 21 reports on H. pylori Adhesive Factors in H. pylori originated in Chile, and 13 of them appeared in indexed interna-H. pylori adherence was studied in strains isolated from patients with DUs and gastritis. Adherence and hemagglutination were tested in HEp-2 cell monolayers and human RBCs, with liquid or solid media [14] . In contrast, and as previously revealed that serum antibodies to CagA are highly prevalent, not only among patients with DUs (46/50; 92%) but also in patients with gastritis (43/50; 86%), as well as among asymptomatic volunteers (24/30; 80%) [25a] .
These data suggest that colonization with Cag A-positive strains may not be a sensitive indicator of greater risk of DUs in Chilean subjects. The prevalence rate of serum IgG antibodies to VacA was also not significantly higher in patients with DUs (14/20; 70%) than in those with gastritis (8/20; 40%) (P Å .11) or in asymptomatic volunteers (6/15; 33%) (P Å .15).
In this last study it was assumed that IgG antibodies to CagA and VacA reflect the in vivo expression of both proteins by the infecting strain. In general it has been observed that 46% of H. pylori strains assayed were cytotoxic. Furthermore, the observation of CagA protein with the blot assay does not always correlate with vacuolating activity as measured in vitro. CagA-positive, while only 10 (63%) synthesized VacA. These results may be due to the presence of more than one infecting strain in the past or during the present infection. treated with homologous and heterologous human sera with and without antibodies to H. pylori. HEp-2 cell assay revealed that sera from colonized patients (with specific antibodies) in- so far are highly susceptible to antibiotics, i.e., metronidazole resistance is rather low (4.2%). Therefore, this trait is not helpful for differentiating between strains from various sources.
Vacuolizing Cytotoxin
Plasmids. Plasmids are common in isolates from Chilean One study aiming to detect vacuolizing cytotoxin (VacA) in patients; some 47% of isolates harbor 1 -3 small plasmids (beChilean H. pylori isolates showed this cytotoxin in five (71%) tween 2.6 and 8.4 mD). However, none of these extrachromoof seven strains from patients with DUs [15] . This study also somal elements are apparently related to antibiotic resistance showed that characteristic changes induced by VacA in HeLa or any other obvious phenotypic trait. cell monolayers could be inhibited by homologous sera but not
Outer-membrane protein profiles. These are of limited use by sera lacking specific antibodies to H. pylori. Western blot because most strains assayed so far have had similar profiles tests unveiled that sera from patients colonized by cytotoxic [25b, 25c] . strains usually recognized an 87-kD protein (VacA), while
According to these studies, it may be concluded that different those infected by strains without this cytotoxin did not have approaches may be needed; perhaps ribotyping or restriction evidence of a VacA-compatible antigen. Although the number analysis may be more useful for identifying H. pylori strains of samples analyzed was rather small (n Å 7), these findings in the Chilean population. suggest that cytotoxic strains are highly prevalent in Chilean patients with DUs, at rates similar to those reported from other Epidemiological Studies on H. pylori areas of the world.
Others have observed that VacA (87 kD) and cytotoxin- (FONDECYT 0249, 1995) upper GI endoscopy. In this study, CLO (H. pylori -like) bacteria were observed in biopsy specimens from 8 of 10 patients, aims to elucidate whether 120-kD antigen could be used as a virulence marker to predict severity of H. pylori colonization and Campylobacter pyloridis was recovered from 5 of them [7] . Subsequent studies in this laboratory [8, 9] and other laboin individuals in the Chilean population. Preliminary results
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10-20-97 09:25:02 cida UC: CID is quite frequent among adult dyspeptic patients in Chile (table 1). The incidence of H. pylori infection ranged between 50% and 88% in patients with DUs [8, 9, 16] , and in patients with for upper GI endoscopy for suspected gastroduodenal patholwell-defined gastritis it was also high, ranging from 67% to ogy had high serum titers of IgG antibody to H. pylori. How-92% [5, 8, 9, 20] . It is interesting that there were no obvious ever, most asymptomatic adults (76%) also had elevated titers differences in the infection rates between patients from the of antibody to H. pylori. Immunoblot assays with EIA-reactive northern, central, and southern parts of Chile. In addition, rates serum specimens recognized multiple antigenic epitopes. As of H. pylori colonization in dyspeptic children have ranged expected, EIA-negative sera had low reactivity in blots. Simifrom 6% to 100% (table 2). Differences in socioeconomic status larly, the prevalence of specific antibodies to H. pylori was and selection of patients may explain the wide range observed. also high in symptomatic children aged 8 -16 years old [3] . Although information on patients with nonulcerative dyspepOne study using an in-house EIA to identify IgG, IgA, and sia is limited, two reports suggest that the rate of H. pylori cell-mediated immune response to H. pylori in patients with colonization is also high among Chilean patients with this conDUs, patients with gastritis, and normal individuals (by histoldition. Infection rates range between 43% and 79% [16, 20] , ogy), confirmed that all patients with DUs as well as those quite comparable with those reported from other countries.
with gastritis (96%) had elevated titers of IgG to H. pylori, while noncolonized individuals with normal histology usually lacked such antibodies (P õ .01) [13] . We also have learned
Serological Studies
that sera with similar EIA values may yield different patterns One serological study, based on an in-house EIA, determined in blots, suggesting that some epitopes are not regularly present levels of specific IgG antibodies to H. pylori among patients in all local strains. One important distinctive pattern was related with DUs, septicemic adults, and asymptomatic Chilean volunto the high molecular weight epitope, Ç120 kD (compatible teers [10] . According to this study, 98% of patients referred with CagA protein), for which some sera had a strong immune response, while others did not recognize it. In summary, serological studies conducted in different Chil- isolates tested so far, and no differences were apparent between On admission all patients were clinically assessed with upper strains obtained on admission and those isolated after combina-GI endoscopy, gastric mucosal studies (histology, urease level tion therapy. The only exception was metronidazole resistance, determination, and culture), and serology (for IgG antibodies in which there was a clear rise, from zero at baseline to 25% to H. pylori, by EIA and immunoblot). Follow-up was done at after therapy. Nevertheless, antibiotic resistance was implicated 28 days (end of treatment) and at 4, 8, and 12 months after in therapeutic failure in only two (3.5%) of the 57 cases, in treatment ended. No maintenance therapy was indicated. Shortwhich evidence suggested antibiotic resistance as a major cause term results (at 28 days) revealed a high and similar ulcerof eradication failure and/or ulcer recurrence. healing rate in both groups of patients (three-drug therapy vs.
Despite long-term treatment, the follow-up compliance was omeprazole alone) (table 4). In contrast, the combination thergood in both groups. There were only eight dropouts due to apy with three drugs achieved H. pylori eradication in a sigpoor compliance; in all these patients H. pylori failed to be nificantly greater proportion of colonized patients with DUs eradicated. A total of 47 patients who had H. pylori eradicated than in those treated with omeprazole alone (table 5) .
were followed-up for a total of 541 posteradication months. The combination therapy with three drugs also significantly Given that only two of these individuals became recolonized (P õ .05) [11] reduced ulcer recurrences noted at the 1-year in this period of time, the reinfection rate for this Chilean follow-up (figure 2). It is of importance that in this study 14 population was calculated to be 4.2 patients/year. This recurpatients with recurrent DUs refractory to omeprazole were inrence rate is barely superior to that of 2.5% reported in 1993 cluded. All these patients' conditions improved after open tri- by Cuttler and Schubert in the United States [28] for the first year following combination therapy with three drugs. It is generally accepted that the rate of H. pylori reinfection in industrialized areas is about 1% per year [29, 30] . In contrast, in low socioeconomic populations reinfection rates are much higher, between 10% [31, 32] and 100% (in Peru) [33] at 1 year following eradication. These data would suggest that in this respect Chile is in an intermediary stage between developed and developing regions. It seems important for health policy planners to take into account local information before discouraging the use of triple-drug therapy as a good therapeutic alternative in some developing countries.
In conclusion, this study suggests that combined therapy with three drugs is a cost-effective treatment with excellent response: it induces clinical improvement, heals DUs, eradicates H. pylori, and significantly reduces recurrence among Chilean patients [11] . In addition, at the end of this study it was shown that for 9 (12%) of 74 patients (of whom 7 received omeprazole and 2 received combination therapy with 3 drugs), antral biopsies for H. pylori were negative while corpus biopsies were positive. This finding confirms other reports that H. pylori may shift from its ecological niche in the antrum to the gastric corpus during treatment. This migration could have led to false-negative results, had only antral biopsies been per- NOTE. Amox Å amoxicillin; BSS Å bismuth subsalicylate; dnr Å doses not reported; DUs Å duodenal ulcers; Famo Å famotidine; Met Å metronidazole; ND Å not determined; NR Å not reported; NUD Å nonulcerative dyspepsia; Ome Å omeprazole; Tin Å tinidazole. * Children.
specific IgG antibodies to H. pylori (figure 4), as measured H. pylori infection. Future actions should include coordinated protocols at national and regional levels. Public health authoriby the in-house standardized EIA. The prospective serological follow-up revealed that omeprazole-treated patients maintained ties should convene investigators, clinicians, and industry-related researchers to develop strategies for reducing and eventuor even increased their levels of specific IgG to H. pylori, while those patients receiving combination therapy with three drugs ally eliminating the considerable expenses caused by H. pyloriassociated pathology. became H. pylori -negative and had a significant fall in specific IgG antibody titers. Progression of the negative serology was evident with rates of 17%, 60%, 74%, and 76% at 28 days, 4
